I had a patient just last week who came to me with a positive pregnancy test yet an ultrasound that revealed nothing about the pregnancy’s location. This is what we refer to in the medical community as a Pregnancy of Unknown Location (PUL). Now, that sounds unsettling, doesn’t it? In reality, while it’s understandable for patients to feel anxious, this isn’t an uncommon scenario, especially in the realm of IVF.
A PUL occurs when your beta HCG levels—those crucial hormones indicating pregnancy—are positive, but the ultrasound can’t yet pinpoint the pregnancy. It’s a bit like investing in a startup; you know there’s potential there, but the outcome isn’t visible yet. In IVF, the excitement of a positive pregnancy test can quickly turn into confusion and concern when the ultrasound doesn’t confirm what we all hope to see—a gestational sac developing in the uterus.
So, why can’t we see the pregnancy on the ultrasound yet? It all boils down to timing and biology. The key player here is the HCG level. We need that level to reach about 1000 mIU/ml—what we call the “discriminatory zone”—before the ultrasound can reliably show the gestational sac. Before this threshold, the sac is simply too small to show up on the scan, much like waiting for a startup’s product to hit market readiness.
But what does PUL mean for you if you’ve undergone IVF? Let me break it down. It’s essential to monitor your HCG levels closely, every two to three days. These numbers should ideally double every 48-72 hours in a healthy pregnancy. If they do, it’s a strong indication that the pregnancy is progressing well, and soon enough, the ultrasound will reveal what we’re hoping for—a healthy, intrauterine pregnancy.
However, not all PUL cases resolve this way. Here’s where the uncertainty of medicine mirrors the unpredictability of early-stage investing. The potential outcomes of a PUL include a normal intrauterine pregnancy, a biochemical pregnancy (where the pregnancy resolves spontaneously), an early miscarriage, or an ectopic pregnancy. Each of these scenarios requires a different approach and understanding.
A biochemical pregnancy, though disappointing, is nature’s way of correcting what might not have developed properly. In this case, your HCG levels may decline on their own. It’s akin to a startup pivoting away from a flawed product before it goes to market. It’s a tough pill to swallow, but it’s part of the journey.
An early miscarriage is another possibility. It’s a difficult experience, and one that demands emotional and physical healing. Much like dealing with a failed business venture, there’s a need for reflection and recovery before moving forward. For those encountering a failed IVF cycle, it’s worth considering how soon you might try again, and I’ve discussed this in more detail here.
The most concerning outcome, albeit rare, is an ectopic pregnancy, where the embryo implants outside the uterus, often in the fallopian tubes. This can be dangerous if not diagnosed early, reflecting how a risky investment can spiral if not managed with vigilance. Early diagnosis and treatment are crucial, much like how a startup needs prompt intervention to navigate a crisis.
The management of PUL requires a careful balance. We must avoid overtreatment, which could potentially harm a viable intrauterine pregnancy. Yet, we must also be vigilant for the signs of an ectopic pregnancy, which demands immediate attention. It’s a delicate dance, much like managing a startup’s growth without stifling innovation or risking collapse.
In my practice, I emphasize open communication and frequent follow-ups with my patients. We monitor HCG levels and schedule ultrasounds as soon as the HCG levels suggest it’s appropriate. This vigilant monitoring mirrors how an angel investor keeps a close eye on their portfolio companies, ensuring they have the support and resources needed to thrive.
Every PUL case is unique, and the path forward depends on many factors. As a doctor and an investor, I’ve learned that uncertainty is part of the process. What matters most is how we navigate it. Whether in medicine or business, the key is to remain informed, patient, and ready to adapt. The journey might be unpredictable, but with careful management, it can lead to the success we hope for.
In this way, the principles I apply in medicine often mirror those in investing. Both require a deep understanding of risk, a capacity for patience, and an unwavering commitment to the people involved. So, if you find yourself encountering a PUL, remember that with the right approach and support, there’s every chance of a positive outcome. Just like nurturing a startup, it’s about managing uncertainty with care and optimism.